PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34338398-0 2021 Local anesthetic bupivacaine inhibits proliferation and metastasis of hepatocellular carcinoma cells via suppressing PI3K/Akt and MAPK signaling. Bupivacaine 17-28 AKT serine/threonine kinase 1 Homo sapiens 122-125 33777755-0 2021 The Local Anesthetic Bupivacaine Inhibits the Progression of Non-Small Cell Lung Cancer by Inducing Autophagy Through Akt/mTOR Signaling. Bupivacaine 21-32 AKT serine/threonine kinase 1 Homo sapiens 118-121 33777755-9 2021 The treatment of bupivacaine attenuated the phosphorylation of AKT and mTOR in the NSCLC cells. Bupivacaine 17-28 AKT serine/threonine kinase 1 Homo sapiens 63-66 33777755-10 2021 The AKT activator SC79 and autophagy inhibitor 3-methyladenine (3-MA) reversed the bupivacaine-inhibited phosphorylation of AKT and mTOR and bupivacaine-induced autophagy, as well as the bupivacaine-attenuated NSCLC progression in the cells. Bupivacaine 83-94 AKT serine/threonine kinase 1 Homo sapiens 4-7 33777755-10 2021 The AKT activator SC79 and autophagy inhibitor 3-methyladenine (3-MA) reversed the bupivacaine-inhibited phosphorylation of AKT and mTOR and bupivacaine-induced autophagy, as well as the bupivacaine-attenuated NSCLC progression in the cells. Bupivacaine 83-94 AKT serine/threonine kinase 1 Homo sapiens 124-127 33777755-10 2021 The AKT activator SC79 and autophagy inhibitor 3-methyladenine (3-MA) reversed the bupivacaine-inhibited phosphorylation of AKT and mTOR and bupivacaine-induced autophagy, as well as the bupivacaine-attenuated NSCLC progression in the cells. Bupivacaine 141-152 AKT serine/threonine kinase 1 Homo sapiens 4-7 33777755-10 2021 The AKT activator SC79 and autophagy inhibitor 3-methyladenine (3-MA) reversed the bupivacaine-inhibited phosphorylation of AKT and mTOR and bupivacaine-induced autophagy, as well as the bupivacaine-attenuated NSCLC progression in the cells. Bupivacaine 141-152 AKT serine/threonine kinase 1 Homo sapiens 4-7 33777755-12 2021 In conclusion, we discovered that the local anesthetic bupivacaine inhibited the progression of NSCLC by inducing autophagy through Akt/mTOR signaling. Bupivacaine 55-66 AKT serine/threonine kinase 1 Homo sapiens 132-135 34659643-10 2021 In addition, phosphatidyl-3-kinase (PI3K)/AKT signaling in neurons was inhibited after exposure to bupivacaine. Bupivacaine 99-110 AKT serine/threonine kinase 1 Homo sapiens 42-45 34659643-11 2021 After PI3K/AKT signaling was inhibited, bupivacaine-mediated DNA damage was further aggravated, and the expression of XPD was further upregulated. Bupivacaine 40-51 AKT serine/threonine kinase 1 Homo sapiens 11-14 34659643-13 2021 In conclusion, the repair enzyme XPD, which was partially regulated by PI3K/AKT signaling, responded to bupivacaine-mediated neuronal DNA damage. Bupivacaine 104-115 AKT serine/threonine kinase 1 Homo sapiens 76-79 34338398-8 2021 Transcriptome sequencing of HepG2 cells suggested that PI3K/Akt and MAPK signaling pathways were suppressed by bupivacaine treatment. Bupivacaine 111-122 AKT serine/threonine kinase 1 Homo sapiens 60-63 34338398-9 2021 In western blot analysis, bupivacaine reduced the expression of total and phosphorylated Akt, mTOR, and MAPK. Bupivacaine 26-37 AKT serine/threonine kinase 1 Homo sapiens 89-92 34338398-10 2021 Furthermore, reactivated PI3K/Akt and MAPK signaling by EGF or NRG1 partially reversed the effects of bupivacaine on cell growth, colony formation, and invasion of HCC cells. Bupivacaine 102-113 AKT serine/threonine kinase 1 Homo sapiens 30-33 32145095-0 2020 Bupivacaine inhibits angiogenesis through oxidative stress-dependent inhibition of Akt/mTOR and activation of AMPK. Bupivacaine 0-11 AKT serine/threonine kinase 1 Homo sapiens 83-86 34307889-11 2021 Conclusion: Dex reduced Bupi-induced vasopermeability through protein expression of ZO-1 and PI3K/Akt pathway, which may lead to the decrease of Bupi-induced cardiotoxicity. Bupivacaine 24-28 AKT serine/threonine kinase 1 Homo sapiens 98-101 34307889-11 2021 Conclusion: Dex reduced Bupi-induced vasopermeability through protein expression of ZO-1 and PI3K/Akt pathway, which may lead to the decrease of Bupi-induced cardiotoxicity. Bupivacaine 145-149 AKT serine/threonine kinase 1 Homo sapiens 98-101 35246010-0 2022 Bupivacaine modulates the apoptosis and ferroptosis in bladder cancer via phosphatidylinositol 3-kinase (PI3K)/AKT pathway. Bupivacaine 0-11 AKT serine/threonine kinase 1 Homo sapiens 111-114 35246010-13 2022 Besides, bupivacaine attenuated the phosphorylation of PI3K, Akt, and mTOR. Bupivacaine 9-20 AKT serine/threonine kinase 1 Homo sapiens 61-64 35246010-14 2022 In addition, bupivacaine suppressed the growth of xenografted tumors, induced apoptosis and ferroptosis, and inhibited the activity of PI3K/AKT signaling pathway in xenografted tumors. Bupivacaine 13-24 AKT serine/threonine kinase 1 Homo sapiens 140-143 35246010-15 2022 Bupivacaine could induce apoptosis and ferroptosis by inhibiting PI3K/Akt signaling pathway in bladder cancer cells. Bupivacaine 0-11 AKT serine/threonine kinase 1 Homo sapiens 70-73 32145095-5 2020 Mechanism analysis indicates that bupivacaine inhibits mitochondrial respiration via decreasing mitochondrial respiratory activity of complex I and II but not IV or V, resulting in energy depletion, oxidative stress, inhibition of Akt/mTOR and activation of AMPK pathway. Bupivacaine 34-45 AKT serine/threonine kinase 1 Homo sapiens 231-234 32145095-6 2020 The rescue of an antioxidant NAC on the effects of bupivacaine confirms that bupivacaine inhibits angiogenesis through oxidative stress-dependent inhibition of Akt/mTOR and activation of AMPK. Bupivacaine 51-62 AKT serine/threonine kinase 1 Homo sapiens 160-163 32145095-6 2020 The rescue of an antioxidant NAC on the effects of bupivacaine confirms that bupivacaine inhibits angiogenesis through oxidative stress-dependent inhibition of Akt/mTOR and activation of AMPK. Bupivacaine 77-88 AKT serine/threonine kinase 1 Homo sapiens 160-163 31190744-0 2019 Andrographolide attenuates bupivacaine-induced cytotoxicity in SH-SY5Y cells through preserving Akt/mTOR activity. Bupivacaine 27-38 AKT serine/threonine kinase 1 Homo sapiens 96-99 31180558-9 2019 Additionally, bupivacaine inhibited protein kinase B (Akt)/mammalian target of rapamycin (mTOR)/S6 kinase (S6K) signaling, which is a negative regulator of autophagic activity. Bupivacaine 14-25 AKT serine/threonine kinase 1 Homo sapiens 54-57 31180558-11 2019 The findings indicated that application of clinically relevant concentrations of bupivacaine upregulated autophagic activity via inhibition of Akt/mTOR/S6K signaling. Bupivacaine 81-92 AKT serine/threonine kinase 1 Homo sapiens 143-146 32894054-10 2020 In addition, maternally administered bupivacaine could significantly decrease hippocampal P.Akt/T.Akt ratio which was concurrent with an increment of cleaved caspase-3 and caspase-8 expression. Bupivacaine 37-48 AKT serine/threonine kinase 1 Homo sapiens 92-95 32894054-10 2020 In addition, maternally administered bupivacaine could significantly decrease hippocampal P.Akt/T.Akt ratio which was concurrent with an increment of cleaved caspase-3 and caspase-8 expression. Bupivacaine 37-48 AKT serine/threonine kinase 1 Homo sapiens 98-101 32894054-11 2020 CONCLUSION: Our data suggest that maternal bupivacaine use increases fetal hippocampal cell apoptosis markers such as caspase 8 and cleaved caspase 3, at least in part, via inhibiting the Akt activation. Bupivacaine 43-54 AKT serine/threonine kinase 1 Homo sapiens 188-191 26646023-7 2016 RESULTS: Bupivacaine cardiotoxicity rapidly dephosphorylated Akt at S473 to 63 +- 5% of baseline and phosphorylated AMPK to 151 +- 19%. Bupivacaine 9-20 AKT serine/threonine kinase 1 Homo sapiens 61-64 26646023-11 2016 Irreversible inhibition of Pi3k upstream of Akt exacerbated bupivacaine cardiotoxicity, whereas pretreating with a reversible inhibitor delayed the onset of toxicity. Bupivacaine 60-71 AKT serine/threonine kinase 1 Homo sapiens 44-47 26646023-13 2016 CONCLUSION: Glucose handling by Akt and AMPK is integral to recovery from bupivacaine cardiotoxicity and modulation of these pathways by ILE contributes to lipid resuscitation. Bupivacaine 74-85 AKT serine/threonine kinase 1 Homo sapiens 32-35 27233246-0 2016 Curcumin Attenuated Bupivacaine-Induced Neurotoxicity in SH-SY5Y Cells Via Activation of the Akt Signaling Pathway. Bupivacaine 20-31 AKT serine/threonine kinase 1 Homo sapiens 93-96 27233246-10 2016 More significantly, the pharmacological inhibition of Akt abolished the cytoprotective effect of curcumin against bupivacaine-induced cell injury. Bupivacaine 114-125 AKT serine/threonine kinase 1 Homo sapiens 54-57 27233246-11 2016 Our data suggest that pretreating SH-SY5Y cells with curcumin provides a protective effect on bupivacaine-induced neuronal injury via activation of the Akt signaling pathway. Bupivacaine 94-105 AKT serine/threonine kinase 1 Homo sapiens 152-155 26809062-0 2016 Lipid emulsion reverses bupivacaine-induced apoptosis of h9c2 cardiomyocytes: PI3K/Akt/GSK-3beta signaling pathway. Bupivacaine 24-35 AKT serine/threonine kinase 1 Homo sapiens 83-86 24605337-3 2014 Although inhibition of Erk, Akt, and AMPK seemingly appears to mediate some of the bupivacaine effects, potential downstream targets that mediate its effect remain unknown. Bupivacaine 83-94 AKT serine/threonine kinase 1 Homo sapiens 28-31